Maven’s MBO Fund II backs healthcare brand specialist, Covestus

Maven's MBO Fund II, alongside other Maven client funds, has committed up to £15 million, to support the buy and build strategy of Covestus, a fast-growing consumer healthcare group.

The initial investment will support the acquisition of two established oral care brands, UltraDEX and Dentyl, from Venture Life Group PLC. The transaction supports the start of an ambitious consolidation strategy aimed at creating a scaled platform of specialist healthcare brands addressing chronic conditions and preventative health needs.

Covestus is headquartered in Cheltenham and operates in the consumer healthcare sector, focusing on brands with strong clinical credentials and clear opportunities to improve brand recognition, product distribution or to pursue new product development opportunities. Its existing portfolio includes Probio7, a leading gut health supplement brand, and Sweatguard, a clinically proven solution for hyperhidrosis.

The addition of UltraDEX, a clinically supported halitosis treatment range, and Dentyl, a leading mouthwash brand, expands Covestus’ footprint in oral care and strengthens its position in the UK and international markets. Both brands have extensive distribution across major retailers and e-commerce platforms, providing an excellent foundation for growth through targeted investment and brand revitalisation.

Covestus is led by a highly experienced management team with extensive experience of building brands and delivering shareholder returns. Executive Chair Tim Wright is an experienced beauty and wellness specialist, with a track record of delivering strong investor returns from M&A led strategies. CEO Quentin Higham brings extensive expertise in value creation strategies from his tenure at AIM-listed Brand Architekts. Together, they combine deep sector knowledge with proven experience in brand development, expanding brands to new markets and M&A.

The consumer healthcare market is experiencing strong growth, driven by increasing consumer demand for self-care and wellness solutions. Maven’s backing will enable the group to execute a pipeline of acquisitions and deliver the bespoke value creation plans for each asset.

“This investment underlines MBO Fund II’s focus on partnering with high-calibre management teams to deliver focused value creation strategies. Covestus is led by an experienced team with a proven track record of operational improvement and transformational growth. The business also operates in a resilient and growing segment of the consumer healthcare market, and the senior leadership team has set out a clear buy-and-build plan to scale through targeted acquisitions and brand development.”

Tom Purkis, Partner at Maven

“Covestus brings a differentiated approach to consumer healthcare by combining clinical credibility with modern beauty-led brand building. The Group is focused on solving highly personal, often chronic conditions through products that are both effective and beautifully designed.

This fusion of science, design and consumer insight positions Covestus to meet the growing demand for self-care solutions that deliver real outcomes while resonating emotionally with consumers. With Maven’s support, the business is well placed to accelerate innovation, expand internationally and build a portfolio of category leading brands.”

Tim Wright, Executive Chair at Covestus